Prescription-to-heroin transition

The Prescription-to-heroin transition is a recurring route into heroin use in which prescription opioids are the initial drug. In the book, it connects the growth of opioid prescribing and the promotion of pain medication to the later spread of heroin use, but it is not presented as an inevitable sequence for every person. Its significance lies in showing how a crisis often framed as a problem of illicit drugs also took shape through medical practice, commercial messaging, and gaps between treatment and criminal justice.

From pain treatment to expanded prescribing

OxyContin entered a medical landscape that was changing how pain was assessed. In 1996, as doctors, hospitals, and accreditation bodies adopted the idea of pain as the fifth vital sign, patients’ subjective reports of pain gained a more formal place in care. The Joint Commission on Accreditation of Healthcare Organizations made pain assessment and treatment mandatory in new standards in 1999. The shift responded to genuine concern that pain had long been undertreated, but it also encouraged the measurement and standardization of an experience that could not be assessed as objectively as blood pressure or temperature.

Purdue Pharma saw the standards as an opportunity to present itself as a leader in pain management. Its budget plan anticipated materials to help hospitals meet the new requirements; the company planned to distribute $300,000 in OxyContin-branded scroll pens, $225,000 in resource binders, and $290,000 in wall charts and clipboards promoting pain as the fifth vital sign. This commercial effort accompanied wider changes in pharmaceutical marketing: advertising spending rose from $360 million in 1995 to $1.3 billion in 1998, while drug companies increasingly used gifts and other promotional strategies to reach physicians.

The company’s reassurance about addiction risk formed part of this environment. David Haddox, Purdue Pharma’s point man for OxyContin, promoted the claim that addiction was rare when the medicine was taken as prescribed. The book contrasts that confidence with later recognition that pain scales could make treatment appear more precise than it was, and that reliance on those scales was associated with increased opioid prescribing and abuse. The transition to heroin is therefore set against a broader history of expanding prescription use, not reduced to a single claim about one drug or one decision.

A documented route, not a universal sequence

The book gives a striking measure of the connection: a cited study reported that 79.5 percent of people newly initiating heroin use in the National Survey on Drug Use and Health said a prescription opioid had been their initial drug. Its index also traces prescription-to-heroin progression across accounts of suburban and rural use, heroin distribution, and overdose. Together, these details establish the transition as an important population-level pattern while leaving room for different individual paths.

The distinction matters. A statistic about initial drug use does not, by itself, explain when or why a person moves from prescription medication to heroin. Nor does it establish that every person who uses prescription opioids will later use heroin. The book’s reporting instead places the pattern alongside stories of addiction, relapse, and overdose, and asks what circumstances and institutional failures leave families trying to reconstruct a progression after the fact.

Families, stigma, and treatment gaps

That search for an explanation is embodied in Kristi Fernandez’s effort to understand the rapid course of her son Jesse Bolstridge’s addiction and fatal overdose. She wants a sufficiently clear account of what happened to Jesse to help other parents recognize danger, yet the story does not readily add up for her. Her questions give the transition a human scale without pretending that one family’s loss supplies a complete explanation for a national trend.

The book also describes how shame made the crisis harder to see and respond to. When reporting began in 2012, many families were reluctant to speak publicly; years later, more were willing to be identified, though some still feared consequences for their work or safety. In another account, two mothers met at a Families Anonymous gathering and found common ground in caring for sons affected by addiction. Their experiences expose the distance between health care and criminal justice systems, while the people with addiction and their relatives struggle to survive within the gaps between them.

Treatment itself could carry stigma. Tess Henry had attended twelve-step meetings but felt judged for taking buprenorphine, which some participants regarded as not being clean. Although Narcotics Anonymous officially accepted medication-assisted treatment, members asked to sponsor or mentor her declined. The episode shows that the transition into addiction and the effort to leave it are shaped not only by drug exposure, but also by whether available communities and institutions recognize treatment as recovery.

Meaning and limits of the concept

The prescription-to-heroin route links clinical practice to an illicit drug epidemic without making the two identical. The book places it against pain-management standards, commercial promotion, family silence, and uneven treatment support; it also records that regulation and enforcement formed part of the changing landscape around opioid use. These connections complicate an account that treats heroin use solely as a matter of individual choice or criminality.

At the same time, the transition is a pattern to investigate, not a complete explanation. The reported proportion of new heroin initiates identifies a strong connection between prescription opioids and later heroin use, while individual stories preserve the uncertainty, variation, and unanswered questions behind that figure. The concept’s force comes from holding both scales together: a measurable public-health pattern and the intimate, incomplete work of families trying to understand what happened to someone they loved.